1. Introduction {#sec1}
===============

The central melanocortin system is essential in maintaining energy balance [@bib1]. Hypothalamic pro-opiomelanocortin (POMC) and agouti gene-related protein (AgRP) as well as their downstream receptor targets comprise the melanocortin system [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11]. POMC is a precursor polypeptide that is synthesized in the pituitary gland as well as the arcuate nucleus (Arc) of the hypothalamus. POMC is enzymatically cleaved to generate small bioactive peptides including α-melanocyte stimulating hormone (MSH), which acts through melanocortin receptors 3 and 4 (MC3/4R) to control energy homeostasis [@bib12], [@bib13]. Moreover, the melanocortin system is a downstream target for the hunger suppressing hormone leptin [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19]. Deficiency of either POMC, MC4R or leptin causes obesity in rodents and humans due to a combination of increased food intake and reduced energy expenditure [@bib4], [@bib10], [@bib11], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27]. MC3R deficiency increases fat mass, but not overall body weight, in mice [@bib28] and is an important regulator of the fasting response [@bib29]. Altogether, the components of the melanocortin system play a critical role in body weight regulation.

We recently identified the function of hypothalamic ArcPOMC in renal proximal tubular glucose reabsorption [@bib30]. We demonstrated that obese and insulin resistant Arc*Pomc*^−/−^ mice exhibit improved glucose tolerance associated with a decreased blood glucose threshold for glycosuria and reduced renal GLUT2, but not SGLT2 glucose transporter levels. However, the molecular mechanisms that couple glucose reabsorption with hypothalamic POMC remain unclear. It is known that hypothalamic melanocortin signaling via MC4R is critical in maintaining sympathetic outflow in rodents [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36] and humans [@bib37]. Consequently, MC4R-deficient mice and humans do not display hypertension despite obesity and insulin resistance [@bib31], [@bib34]. Similarly, pharmacological activation and inhibition of MC4R increases and reduces blood pressure, respectively [@bib38], [@bib39], [@bib40]. Moreover, MC4R mediates a leptin-induced increase in renal sympathetic nerve activity (RSNA) in mice [@bib39]. MC4R is also involved in early life programming of hypertension resulting either from maternal obesity or exposure to hyperleptinemia [@bib41]. In addition to MC4R, POMC neurons are implicated in mediating leptin-induced hypertension [@bib42], and administration of POMC peptides such as α-MSH and ACTH increases blood pressure [@bib43]. Overall, these reports indicate a direct role of ArcPOMC in regulating sympathetic outflow.

Reduced RSNA, accomplished by renal denervation, improves glucose tolerance in drug-resistant hypertensive patients [@bib44], [@bib45]. However, the mechanisms underlying this beneficial effect are unclear. Our previous report [@bib30] indicates that Arc*Pomc*^−/−^ mice exhibit improved glucose tolerance due to elevated glycosuria. Given the function of the central melanocortin system in the regulation of sympathetic outflow [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib43], we hypothesized that reduced RSNA leads to elevated glycosuria in Arc*Pomc*^−/−^ mice. To test this hypothesis, we measured RSNA in Arc*Pomc*^−/−^ mice and determined glucose regulation in renal-denervated wild type (WT) and diabetic *db/db* mice. We also delineated the impact of renal denervation on levels of the renal proximal tubular glucose transporters GLUT2 and SGLT2 using western blotting and immunohistochemistry.

2. Methods {#sec2}
==========

2.1. Animal care and high-fat diet protocol {#sec2.1}
-------------------------------------------

All procedures were approved by the Institutional Animal Care and Use Committees at the University of Michigan and University of Iowa and followed the Public Health Service guidelines for the humane care and use of experimental animals. Mice were housed in ventilated cages under a controlled temperature (∼23 °C) and photoperiod (12 h light/dark cycle, lights on from 6:00 a.m. to 6:00 p.m.) and fed tap water and laboratory chow (5L0D; LabDiet) containing 28.5 kcal% protein, 13.5 kcal% fat, and 58 kcal% carbohydrate. A separate cohort of mice was fed with either the regular chow or high-fat diet (HFD, OpenSource Diets®, D12451 -- 20 kcal% protein, 45 kcal% fat, and 35 kcal% carbohydrate) immediately after weaning for 16 weeks. Moreover, a group of female Arc*Pomc*^−/−^ mice was weight-matched to that of WT mice by calorie restriction as described previously [@bib30].

The generation and breeding of Arc*Pomc*^−/−^ mice have been reported previously [@bib11], [@bib30]. Arc*Pomc*^−/−^ mice were backcrossed for at least ten generations onto the C57BL/6J genetic background, and these congenic mice were used throughout the study. Male *db/db* mice and their *db/m* littermate controls were purchased from The Jackson Laboratory (Stock number: 000642). Mice were randomly assigned to different experimental groups throughout the study.

We utilized female Arc*Pomc*^−/−^ mice and their littermates for blood pressure and renal sympathetic nerve activity (RSNA) measurements, kidney histology and urine analysis, and HFD study. Male mice were included for studies involving renal denervation and corresponding urine analysis.

2.2. Measurement of blood pressure and RSNA {#sec2.2}
-------------------------------------------

Mice were anesthetized with an intraperitoneal injection of a ketamine (91 mg/kg)/xylazine (9.1 mg/kg) cocktail. Each mouse was intubated using polyethylene tubing (PE-50) to allow spontaneous breathing of oxygen-enriched air throughout the experimental procedure. Next, a tapered micro-renathane tubing (MRE-040; Braintree Scientific, Inc. Braintree, MA) was inserted into the right jugular vein from which α-chloralose was infused at an initial dose of 12 mg/kg during the surgical preparation then at a sustaining dose of 6 mg/kg/h; until completion of the study. Another tapered MRE-040 tubing was inserted into the left carotid artery for continuous measurement of arterial pressure. The carotid cannula was connected to a low-volume pressure transducer (BP-100; iWorks System, Inc., Dover, NH) that led to an ETH-250 Bridge/Bio Amplifier (CB Sciences; Milford, MA). The filtered, amplified pulsatile pressure signal was directed to an analog--digital acquisition system (MacLab 8S; see below) for continuous display of not only phasic arterial pressure and heart rate but also sympathetic nerve activity on a computer monitor. Core body temperature of the mouse was measured using a rectal probe (YSI 4000A Precision Thermometer; Yellow Springs, OH) and maintained constant at 37.5 °C using a custom-made heated surgical platform.

RSNA was measured by multifiber recording directly from the nerves innervating the kidneys as described previously [@bib46], [@bib47]. Briefly, nerves innervating the left kidney were identified, dissected free, and placed on a bipolar 36-gauge platinum--iridium electrode (A-M Systems; Carlsborg, WA). The electrode was connected to a high impedance probe (HIP-511; Grass Instruments Co., Quincy, MA), and the nerve signal was amplified 10^5^ times with a Grass P5 AC pre-amplifier and filtered at low and high frequency cutoffs of 100 Hz and 1000 Hz, respectively. This nerve signal was directed to a speaker system and to an oscilloscope (54501A, Hewlett--Packard Co., Palo Alto, CA) for auditory and visual monitoring of the nerve activity. The signal was then directed to a resetting voltage integrator (B600C, University of Iowa Bioengineering) that sums the total voltage output in units of 1 V \* sec before resetting to zero and counting the number of spikes per second. The final neurograms were continuously routed to a MacLab analogue--digital converter (8S, AD Instruments Castle Hill, New South Wales, Australia) for permanent recording and data analysis on a Macintosh computer. RSNA was corrected for post-mortem background activity to eliminate background electrical noise in the assessment of sympathetic outflow in the integrated voltage.

2.3. Renal denervation {#sec2.3}
----------------------

Mice were placed in the prone position under general anesthesia with isoflurane. To minimize the invasive approach to the kidneys, a single skin incision was made in the dorsal midline. After exposing the kidneys, renal blood vessels were identified and all visible nerves along the vessels were severed. Furthermore, the vessels were painted with a solution of 10% phenol in absolute ethanol using a fine brush. This treatment did not affect the vessels. After surgery, the paravertebral muscle layers and skin were closed with nylon sutures. Carprofen was administered prior to skin incision and post-operatively for analgesia. Mice were allowed to recover for a week before subjecting them to any experiments. To confirm reduced RSNA post renal denervation procedure, kidney norepinephrine levels were measured as described previously [@bib30] after the completion of all the experiments.

2.4. Glucose and insulin measurements {#sec2.4}
-------------------------------------

Oral glucose tolerance and intraperitoneal insulin tolerance tests were performed as described previously [@bib30]. A fixed dose of glucose (G5767; Sigma, 60 mg/mouse in 300 μl water) was administered rather than a dose adjusted by body weight to eliminate the confounding effects of obesity. For insulin tolerance tests, insulin (Humulin R; Eli Lilly, 0.5 units/kg lean mass) i.p. was administered. The total area under the curve (AUC) was calculated using the trapezoidal rule.

A glucose-stimulated insulin secretion assay was performed according to our published protocol [@bib48].

2.5. Urine glucose and electrolytes {#sec2.5}
-----------------------------------

For 24 h urine collections, mice were housed individually in metabolic cages (Tecniplast) and were allowed to adapt to the cages for 1 week prior to sample collection. Urine was collected for 24 h, and urine glucose was measured by a colorimetric assay as per manufacturer\'s instructions (81692; Crystal Chem). Urine sodium, potassium, and chloride levels were measured using indirect ion-selective electrodes on ADVIA 1800.

2.6. Western blotting and kidney histology {#sec2.6}
------------------------------------------

Western blots were carried out as per our published protocol [@bib30]. Rabbit polyclonal anti-GLUT2 (600-401-GN3; Rockland Immunochemicals) and goat polyclonal anti-SGLT2 (sc-47402; Santa Cruz Biotechnology) primary antibodies were used at 1:2,000 and 1:1,000 dilutions, respectively, in tris-buffered saline with Tween 20 (TBST) containing 5% powdered milk. Secondary antibodies anti-rabbit (NA934; GE Healthcare) and anti-goat IgGs (sc-2768; Santa Cruz Biotechnology) coupled to horseradish peroxidase were used to detect the corresponding primary antibodies bound to their respective target proteins. Vinculin (ab73412; Abcam) levels were quantified on the same membranes as target proteins to confirm equal loading of samples. Luminescence was generated with the Amersham ECL Advance Western Blotting Detection Kit (GE Healthcare) and recorded on a Fotodyne Imaging System.

For immunohistochemistry, kidneys were removed 45 min after oral glucose administration, cut longitudinally into two equal halves, and fixed overnight in 10% neutral buffered formalin. The fixed kidneys were embedded in paraffin and 5 μm sections collected with a microtome. The sections were mounted onto slides, deparaffinized and rehydrated before an antigen retrieval procedure of incubating the slides in sodium citrate buffer (pH 6.0) at 80 °C in a water bath for 1 h. Following this antigen retrieval step, the slides were washed 3 times (10 min/wash) in TBST. The sections were blocked in 10% normal goat serum for 2 h before incubating them with primary antibodies, rabbit anti-GLUT2 (600-401-GN3; Rockland Immunochemicals, 1:500 dilution) or rabbit anti-SGLT2 (ab85626; Abcam, 1:500 dilution), overnight at 4 °C. Following the incubation period, the sections were washed 3 times (10 min/wash) in TBST and then incubated with secondary goat-anti-rabbit serum conjugated to Alexa Fluor 488 (A-11034; Invitrogen, 1:500 dilution) for 1 h at room temperature. The sections were washed again 3 times (10 min/wash) in TBST and counterstained with DAPI (D9542; Sigma, 0.1 μg/ml). After a 5 min wash, the slides were air-dried and coverslipped using ProLong Antifade mounting medium (P36930; Molecular Probes). Images were captured using a Nikon 90i upright microscope (Nikon, Tokyo, Japan) equipped with an X-Cite 120Q fluorescent light source (Lumen Dynamics, Mississauga, Ontario, Canada), and a CoolSNAP HQ2 CD camera (Photometrics, Tucson, AZ).

Hematoxylin and Eosin (H&E) staining was performed on mouse kidney sections to determine changes in glomerular morphology. The sections were mounted onto slides, deparaffinized and rehydrated as described above. The sections were air-dried and incubated in hematoxylin solution (MHS16; Sigma) for 15 min followed by a 15 min wash with running tap water. Thereafter, the slides were counterstained with alcoholic eosin Y solution (HT110116; Sigma) for 1 min, rinsed with tap water, and coverslipped using ProLong Antifade mounting medium.

The quantitative analysis of histological images was performed using Nikon software NIS-Elements AR. Investigators were blinded to the identity of different samples during the analysis.

2.7. Statistics {#sec2.7}
---------------

All data are presented as mean ± SEM. The data were analyzed by Student\'s unpaired 2-tailed *t*-test, or by 2-way or repeated measures (RM) 2-way ANOVA followed by Tukey\'s multiple comparison test as appropriate with GraphPad Prism 7 software. P \< 0.05 was considered significant.

3. Results {#sec3}
==========

3.1. Obese Arc*Pomc*^−/−^ mice have normal blood pressure and reduced RSNA concomitantly with improved glucose tolerance and elevated glycosuria {#sec3.1}
------------------------------------------------------------------------------------------------------------------------------------------------

First, we performed OGTT and measured 24 h urine glucose on two separate occasions in obese Arc*Pomc*^−/−^ mice (Bodyweight: Arc*Pomc*^−/−^ mice, 55.4 ± 1.7 vs. WT mice, 22.9 ± 0.7 g, P \< 0.01). In agreement with our previous study [@bib30], Arc*Pomc*^−/−^ mice exhibited improved glucose tolerance ([Figure 1](#fig1){ref-type="fig"}A) and elevated glycosuria ([Figure 1](#fig1){ref-type="fig"}B). Moreover, to determine a mechanism responsible for elevated glycosuria in Arc*Pomc*^−/−^ mice, we measured RSNA in Arc*Pomc*^−/−^ mice and littermate controls. Obese Arc*Pomc*^−/−^ mice had normal blood pressure ([Figure 1](#fig1){ref-type="fig"}C) and reduced RSNA ([Figure 1](#fig1){ref-type="fig"}D), suggesting an essential role of ArcPOMC in maintaining basal renal sympathetic tone. Together, these data indicate an association of RSNA with glucose reabsorption.Figure 1Improved glucose tolerance and elevated glycosuria associated with reduced renal sympathetic nerve activity in obese 22--24-wk old female Arc*Pomc*^−/−^ mice. A) Improved glucose tolerance in Arc*Pomc*^−/−^ mice; B) Elevated glycosuria in Arc*Pomc*^−/−^ mice; C) Normal blood pressure in Arc*Pomc*^−/−^ mice; D) Reduced renal sympathetic nerve activity (RSNA) in Arc*Pomc*^−/−^ mice. \*P \< 0.05, \*\*\*P \< 0.001, \*\*\*\*P \< 0.0001, 2-tailed Student\'s *t*-test or 2-way RMANOVA followed by Tukey\'s multiple comparison test was used for comparisons as appropriate; n = 6. Error bars reflect mean ± SEM.Figure 1

3.2. Obese Arc*Pomc*^−/−^ mice have decreased proximal tubular GLUT2 levels without any changes in subcellular distribution {#sec3.2}
---------------------------------------------------------------------------------------------------------------------------

Using a western blotting approach in our previous report [@bib30], we attributed elevated glycosuria to reduced renal cortical GLUT2, but not SGLT2, levels in Arc*Pomc*^−/−^ mice. However, it was unclear if changes in proximal tubular subcellular GLUT2 distribution also accounted for decreased glucose reabsorption in Arc*Pomc*^−/−^ mice. Even though we did not see any changes in total SGLT2 levels, there was a possibility that translocation of SGLT2 away from the apical membrane brush border of the proximal tubular cells led to reduced glucose reabsorption. To address these possibilities, we performed immunohistochemistry on kidney sections from WT as well as Arc*Pomc*^−/−^ mice. Consistent with our previous report, Arc*Pomc*^−/−^ mice exhibited decreased GLUT2 ([Figure 2](#fig2){ref-type="fig"}A), but not SGLT2 ([Figure 2](#fig2){ref-type="fig"}B), immunofluorescence. However, there were no changes in the distribution pattern or location of either GLUT2 or SGLT2 transporters. These data indicate that elevated glycosuria is due to overall decreased GLUT2 levels in proximal tubular cells and not translocation of the glucose transporters away from the plasma membrane in Arc*Pomc*^−/−^ mice.Figure 2Immunofluorescence detection of GLUT2 and SGLT2 levels in 24-wk Arc*Pomc*^−/−^ mice. A) Reduced GLUT2 levels in proximal tubular cells, but no change in its distribution or location, in Arc*Pomc*^−/−^ mice; B) No change in proximal tubular SGLT2 levels in Arc*Pomc*^−/−^ mice. \*P \< 0.05, 2-tailed Student\'s *t*-test was used for comparisons; n = 6. Error bars reflect mean ± SEM. Scale bar = 33 μm; images were taken under 40× objective lens field.Figure 2

3.3. Obese Arc*Pomc*^−/−^ mice exhibit glomerular hypertrophy, natriuresis, kaliuresis, and chloriuresis {#sec3.3}
--------------------------------------------------------------------------------------------------------

Obese Arc*Pomc*^−/−^ mice exhibited increased glomerular surface area ([Figure 3](#fig3){ref-type="fig"}A) compared to their WT littermates. However, weight-matched Arc*Pomc*^−/−^ mice had normal glomerular surface area (Arc*Pomc*^−/−^ mice, 3305 ± 321 vs. WT, 2852 ± 308 μm^2^, n = 4, no statistical difference). These data suggest that the glomerular hypertrophy was a secondary consequence of obesity and possibly increased blood volume, but not a direct effect of ArcPomc deficiency. This observation is in accordance with that from MC4R^−/−^ mice [@bib49], and data showing that obesity itself can lead to glomerular hypertrophy [@bib50].Figure 3Glomerular morphology and urine electrolytes in 24-wk old Arc*Pomc*^−/−^ mice. A) Glomerular hypertrophy in obese Arc*Pomc*^−/−^ mice (H&E staining); Elevated B) Natriuresis; C) Kaliuresis; D) Chloriuresis in obese and weight-matched female Arc*Pomc*^−/−^ mice. \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001, 2-tailed Student\'s *t*-test was used for comparisons; n = 6. Error bars reflect mean ± SEM. Scale bar = 33 μm; images were taken under 40× objective lens field. The red arrows point out the glomeruli.Figure 3

Both obese and weight-matched Arc*Pomc*^−/−^ mice had elevated natriuresis ([Figure 3](#fig3){ref-type="fig"}B), kaliuresis ([Figure 3](#fig3){ref-type="fig"}C) and chloriuresis ([Figure 3](#fig3){ref-type="fig"}C). Consequently, obese Arc*Pomc*^−/−^ mice exhibited polydipsia (Water intake per day: Arc*Pomc*^−/−^, 7.4 ± 0.3 ml vs. WT, 6.4 ± 0.2 ml, n = 7--9, P \< 0.05) and polyuria (Urine volume per day: Arc*Pomc*^−/−^, 6.9 ± 0.4 ml vs. WT, 2.7 ± 0.3 ml, n = 7--9, P \< 0.001). However, these latter changes were absent in weight-matched Arc*Pomc*^−/−^ mice (data not shown) possibly due to their calorie restriction. The electrolyte excretion results clearly indicate a function of Arc*Pomc* in the regulation of sodium, potassium and chloride reabsorption, possibly via RSNA.

3.4. Obese Arc*Pomc*^−/−^ mice preserve their β-cell function and the mice are protected from HFD-mediated impaired glucose tolerance {#sec3.4}
-------------------------------------------------------------------------------------------------------------------------------------

Generally, the β-cell compensatory response of enhanced insulin secretion, to overcome the insulin resistance associated with obesity, is decreased over time and leads to hyperglycemia. However, massively obese and insulin resistant aged Arc*Pomc*^−/−^ mice do not manifest hyperglycemia [@bib30]. To elucidate this atypical phenotype, we performed a glucose-stimulated insulin secretion test on isolated islets from 26-wk old Arc*Pomc*^−/−^ mice. Remarkably, the magnitude of insulin secretion was higher in the islets from Arc*Pomc*^−/−^ mice in response to 25 mM glucose compared to that from WT mice (26 wk: Arc*Pomc*^−/−^ mice, 0.13 ± 0.01 vs. WT mice, 0.07 ± 0.01 insulin ng/mg protein, n = 4, P \< 0.05). Basal insulin secretion from the islets in response to 3.3 mM glucose was not different between the two groups (data not shown). These results indicate that the function of β-cells of Arc*Pomc*^−/−^ mice is preserved despite chronic insulin resistance and obesity.

Arc*Pomc*^−/−^ mice were fed a HFD to determine their propensity to develop diet-induced impaired glucose tolerance. The mice consumed a significantly lower mass of HFD compared to that of regular chow per day ([Figure 4](#fig4){ref-type="fig"}A). However, there was no change in the total calorie intake in HFD-fed Arc*Pomc*^−/−^ mice relative to regular chow fed mice ([Figure 4](#fig4){ref-type="fig"}B). The body weight of HFD-fed Arc*Pomc*^−/−^ mice was significantly increased compared to that of the regular chow fed mice ([Figure 4](#fig4){ref-type="fig"}C). Interestingly, despite this further increase in body weight, Arc*Pomc*^−/−^ mice remained protected from HFD-induced fasting hyperglycemia or impaired glucose tolerance ([Figure 4](#fig4){ref-type="fig"}D, E) probably due to their elevated glycosuria ([Figure 4](#fig4){ref-type="fig"}F).Figure 4Impact of high-fat diet (HFD) on glycemia in female Arc*Pomc*^−/−^ mice. A) Reduced mass of daily food intake in HFD fed WT and Arc*Pomc*^−/−^ mice relative to their regular chow (RC) fed controls, \*P \< 0.05 for RC vs. HFD; ^\#\#^P \< 0.01 for RC Arc*Pomc*^−/−^ vs. WT (n = 6), 2-way ANOVA followed by Tukey\'s multiple comparisons test (F~1,\ 17~ = 3.3, P \< 0.05, interaction of genotype and diet); B) No change in daily calorie intake between HFD and RC fed WT or Arc*Pomc*^−/−^ mice. Increased calorie intake in Arc*Pomc*^−/−^ mice relative to WT mice, ^∗∗^P \< 0.01 for Arc*Pomc*^−/−^ vs. WT (n = 6), 2-way ANOVA followed by Tukey\'s multiple comparisons test; C) HFD increases body weight in WT and Arc*Pomc*^−/−^ mice, \*P \< 0.05 for Arc*Pomc*^−/−^ RC vs. HFD, ^\#^P \< 0.01 for WT RC vs HFD, 2-way RMANOVA followed by Tukey\'s multiple comparisons test (F~24,\ 112~ = 91.6, P \< 0.05, interaction of time and genotype); D) No change in fasting blood glucose levels in HFD fed Arc*Pomc*^−/−^ mice relative to their RC controls, but an increase in fasting blood glucose levels in HFD fed WT mice compared to their RC controls, \*P \< 0.05 for WT RC vs. HFD, 2-way ANOVA followed by Tukey\'s multiple comparison test; E) No impairment in glucose tolerance in HFD fed Arc*Pomc*^−/−^ mice; bar-graph shows AUC for the glucose tolerance test, \*P \< 0.05 for WT RC vs. HFD, ^\#\#^P \< 0.05 for Arc*Pomc*^−/−^ RC or HFD vs WT, 2-way ANOVA followed by Tukey\'s multiple comparison test; F) Elevated glycosuria in HFD fed Arc*Pomc*^−/−^ mice. ^∗∗^P \< 0.01 for Arc*Pomc*^−/−^ vs. WT, 2-way ANOVA followed by Tukey\'s multiple comparisons test. KO, Arc*Pomc*^−/−^ mice; RC, regular chow; HFD, high-fat diet; AUC, area under the curve. Error bars reflect mean ± SEM.Figure 4

3.5. Renal-denervated WT and *db/db* mice recapitulate the phenotype of Arc*Pomc*^−/−^ mice {#sec3.5}
-------------------------------------------------------------------------------------------

To further elucidate the function of RSNA in glucose reabsorption, we denervated the kidneys of WT and *db/db* mice. Kidney norepinephrine levels were about 80% lower in the denervated mice relative to their sham-operated controls (WT: 0.06 ± 0.02 vs. 0.28 ± 0.01; *db/db*: 0.08 ± 0.02 vs. 0.35 ± 0.03, ng/mg tissue, renal-denervated vs. sham), thereby validating the renal denervation procedure. We found that renal-denervated WT mice exhibited improved glucose tolerance ([Figure 5](#fig5){ref-type="fig"}A) and elevated glycosuria ([Figure 5](#fig5){ref-type="fig"}B) compared to their WT sham-operated littermates. Insulin sensitivity was not affected by the renal denervation procedure in WT mice ([Figure 5](#fig5){ref-type="fig"}C). These results suggest a critical role of RSNA in glucose reabsorption, independently of insulin action.Figure 5Effects of renal denervation on glycemia in male WT and *db/db* mice. A) Renal denervation improves glucose tolerance in 8--10-wk old WT mice; B) Elevated glycosuria in renal-denervated WT mice; C) No change in insulin sensitivity after renal denervation in WT mice; D) Renal denervation improves glucose tolerance in *db/db* mice; E) Elevated glycosuria in renal-denervated 9-wk old *db/db* mice; F) Reduced glycosuria in renal-denervated 12-wk old *db/db* mice. \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001, 2-tailed Student\'s *t*-test or 2-way RMANOVA followed by Tukey\'s multiple comparison test was used for comparisons as appropriate; n = 6. RD, renal denervation; AUC, area under the curve. Error bars reflect mean ± SEM.Figure 5

The renal-denervation procedure in diabetic *db/db* mice prevented an age-associated increase in their fasting blood glucose levels (Baseline: designated sham group, 288 ± 16 vs. designated renal-denervated group, 334 ± 30, no statistical difference; 9-wk: 451 ± 6 vs 309 ± 10; 12-wk: 459 ± 14 vs 310 ± 8 mg/dl, sham vs. renal-denervated, Student\'s unpaired 2-tailed *t*-test, P \< 0.05). Moreover, renal-denervated *db/db* mice had improved glucose tolerance at different ages compared to their sham-operated littermates ([Figure 5](#fig5){ref-type="fig"}D). This improvement in glucose tolerance was associated with elevated glycosuria in 9-wk old *db/db* mice ([Figure 5](#fig5){ref-type="fig"}E). However, with no further increase in fasting glycemia at 12-wk of age, renal-denervated *db/db* mice showed reduced glycosuria compared to sham-operated *db/db* mice ([Figure 5](#fig5){ref-type="fig"}F). It is important to acknowledge that renal-denervation in *db/db* mice did not completely restore normal glycemia or glucose tolerance; however, the procedure prevented further deterioration of glucose tolerance and hyperglycemia. Overall, our data indicate a direct role of RSNA in glucose reabsorption in normal as well as diabetic mice.

To understand the mechanism underlying elevated glycosuria, we determined the levels of the major renal glucose transporters, GLUT2 and SGLT2. Consistent with the results obtained from Arc*Pomc*^−/−^ mice, we observed reduced renal GLUT2 ([Figure 6](#fig6){ref-type="fig"}A), but not SGLT2 ([Figure 6](#fig6){ref-type="fig"}B), levels in renal-denervated WT and *db/db* mice. These data further reinforce that the sympathetic nervous system controls glucose reabsorption via renal GLUT2.Figure 6Representative western blots showing renal cortical GLUT2 and SGLT2 levels in renal-denervated WT and *db/db* mice. A) Decreased renal cortical GLUT2 levels in renal-denervated WT and *db/db* mice; B) No change in renal cortical SGLT2 levels in renal-denervated WT and *db/db* mice. \*P \< 0.05, 2-tailed Student\'s *t*-test was used for comparisons; n = 8 (4 samples per group on each blot). Error bars reflect mean ± SEM.Figure 6

Like Arc*Pomc*^−/−^ mice, renal-denervated WT and *db/db* mice had elevated natriuresis ([Figure 7](#fig7){ref-type="fig"}A), kaliuresis ([Figure 7](#fig7){ref-type="fig"}B) and chloriuresis ([Figure 7](#fig7){ref-type="fig"}C). Altogether, renal-denervated WT and *db/db* mice recapitulated the phenotype observed in Arc*Pomc*^−/−^ mice. Hence, our study strongly suggests a role of RSNA in glucose homeostasis via modulation of glucose reabsorption.Figure 7Effects of renal denervation on urine electrolytes in male WT and *db/db* mice. Elevated A) Natriuresis; B) Kaliuresis; C) Chloriuresis in renal-denervated WT and *db/db* mice. \*P \< 0.05, \*\*P \< 0.01, 2-tailed Student\'s *t*-test was used for comparisons; n = 6. Error bars reflect mean ± SEM.Figure 7

4. Discussion {#sec4}
=============

In this study, we report the function of Arc*Pomc* in maintaining basal RSNA. Arc*Pomc*^−/−^ mice are protected from hypertension, despite obesity and insulin resistance, because of reduced RSNA. Moreover, utilizing normal and diabetic *db/db* mice, we demonstrate that RSNA contributes to glucose reabsorption via GLUT2 in renal proximal tubular cells. Hence, renal denervation improves glucose tolerance in mice by elevating their glycosuria.

Generally, obesity and insulin resistance are major risk factors for cardiovascular disorders including hypertension [@bib33]. Obesity stimulates sympathetic nervous system activity leading to hypertension [@bib33]. Leptin is the primary mediator for obesity-induced increase in sympathetic nervous system activity and consequent hypertension [@bib40], [@bib51], [@bib52], [@bib53], [@bib54]. Moreover, insulin resistance is associated with hypertension [@bib55], [@bib56], [@bib57]. However, in this study, we demonstrate that despite obesity, insulin resistance and hyperleptinemia, Arc*Pomc*^−/−^ mice remain protected from hypertension due to suppressed RSNA. This phenotype is reminiscent of that of MC4R knockout mice. MC4R-deficient mice do not exhibit increases in RSNA or hypertension despite obesity, insulin resistance and hyperleptinemia [@bib31]. Moreover, MC4R is critical in mediating the leptin-induced increase in RSNA [@bib39]. Hence, our results from Arc*Pomc*^−/−^ mice are in line with that obtained from MC4R knockout mice. Altogether, these data indicate that POMC/MC4R signaling is essential in causing obesity-induced hypertension via regulating RSNA.

We recently reported that Arc*Pomc*^−/−^ mice do not exhibit hyperglycemia despite obesity and insulin resistance [@bib30]. Similarly, it is known that obese and insulin resistant POMC-deficient humans do not develop diabetes [@bib24], [@bib58]. Moreover, neither MC4R knockout mice nor MC4R-deficient humans manifest hyperglycemia in spite of obesity and insulin resistance [@bib20], [@bib23], [@bib59]. We attributed the improvement in glucose tolerance in Arc*Pomc*^−/−^ mice to elevated glycosuria mediated by reduced proximal tubular GLUT2 levels [@bib30]. However, the mechanism that links glucose reabsorption with ArcPOMC is unclear. We have previously observed that epinephrine increases renal GLUT2 levels in mice [@bib30]. Moreover, we showed that Arc*Pomc*^−/−^ mice have reduced epinephrine levels in their kidneys, indicating the role of ArcPOMC in regulating sympathetic nervous system activity. In this study, we directly showed by electrophysiological measurements that Arc*Pomc*^−/−^ mice do have reduced RSNA, consistent with our hypothesis that it is the mechanism for their elevated glycosuria.

To further validate the function of RSNA in glucose reabsorption using alternative mouse models, we denervated kidneys in WT and *db/db* mice. Renal denervation improves glucose metabolism in drug-resistant hypertensive patients [@bib44], [@bib45]. However, the mechanism remains unclear. We found that, like Arc*Pomc*^−/−^ mice, renal-denervated WT and *db/db* mice exhibited improved glucose tolerance in association with elevated glycosuria. As fasting hyperglycemia and glucose tolerance continued to improve in *db/db* mice after renal denervation, glycosuria was subsequently decreased in 12-wk old *db/db* mice. This observation corroborates a previous study that reported a decrease in glycosuria in *db/db* mice after chronic treatment with an SGLT2 inhibitor [@bib60]. Collectively, our data from renal-denervated mice confirm a role of RSNA in glucose reabsorption.

In contrast, a recent study reported that renal denervation does not improve glucose tolerance in obese hypertensive mice [@bib61]. It is very likely that the authors of that report did not see any improvement in glucose tolerance because the mice were administered glucose based on their body weight. Hence, the obese mice received a higher glucose dose compared to lean mice, which might have affected their response to glucose tolerance tests. Moreover, the mice in that study [@bib61] were fasted for 14 h prior to glucose tolerance tests, which is different than our protocol of fasting the mice for only 6 h [@bib30]. These variations, in addition to different routes of administration of glucose, could have led to inconsistent results and conclusions between our present study and that by Asirvatham-Jeyaraj et al. [@bib61].

Interestingly, a link between RSNA and glycosuria was also recently suggested using Otsuka Long-Evans Tokushima fatty rats [@bib62]. The authors removed the right kidney before denervating the left kidney at a later age to determine the role of renal sympathetic nerves in glucose reabsorption. The authors stated that right uninephrectomy was performed to prevent reno-renal reflexes. However, consistent with clinical protocols in humans [@bib44], we suggest that a bilateral renal denervation procedure would have been a more powerful physiological approach to test the impact of renal sympathetic nerves on glucose reabsorption. Moreover, unilateral nephrectomy might have led to compensatory changes in the contralateral kidney in the rats [@bib63]. Besides species differences, these different methodologies might explain why we, unlike Rafiq et al. [@bib62], did not observe any changes in SGLT2 levels post renal denervation. Nevertheless, conclusions from our current study support the main findings from the report by Rafiq et al. [@bib62] that reduced RSNA elevates glycosuria leading to improvement in glucose tolerance.

We previously demonstrated using a western blotting method that elevated glycosuria in Arc*Pomc*^−/−^ mice is due to reduced renal proximal tubular GLUT2, but not SGLT2, levels [@bib30]. Both GLUT2 and SGLT2 are involved in glucose reabsorption. While SGLT2 is a major glucose transporter in the apical brush border membrane of proximal tubular cells, GLUT2 is located at the basolateral membrane of the cells. In the current study, we performed immunohistochemistry to verify the location and distribution of these transporters in Arc*Pomc*^−/−^ mice. GLUT2 in epithelial cells of the intestine is translocated from basolateral membrane to apical brush border membrane in response to meals or elevated glucose [@bib64], [@bib65]. We wanted to determine whether this translocation-phenomenon in proximal tubule cells of the kidney could explain the elevated glycosuria in Arc*Pomc*^−/−^ mice. Consistent with our previous report [@bib30], we observed reduced GLUT2, but not SGLT2, immunofluorescence in renal proximal tubular cells. However, we did not see any change in the location or distribution pattern of either transporter in Arc*Pomc*^−/−^ mice. Nonetheless, differences in SGLT2 or GLUT2 activity between WT and Arc*Pomc*^−/−^ mice cannot be excluded and might further clarify elevated glycosuria in the latter.

Deficiency or inhibition of only SGLT2 [@bib66], [@bib67] or GLUT2 [@bib68], [@bib69] can lead to elevated glycosuria in rodents as well as humans. The elevated glycosuria protects them from hyperglycemia. Moreover, SGLT2 knockout mice remain protected from HFD mediated hyperglycemia and impaired glucose tolerance despite obesity and insulin resistance [@bib70]. Similarly, we demonstrate that obese and insulin resistant Arc*Pomc*^−/−^ mice are protected from HFD mediated impaired glucose tolerance. We further show that islets isolated from aged Arc*Pomc*^−/−^ mice release higher insulin compared to that isolated from their WT littermates in a glucose-stimulated insulin secretion test. During obesity, hyperinsulinemia compensates for insulin resistance to maintain normal blood glucose levels. With time, this compensation fails to overcome insulin resistance leading to overt hyperglycemia due to β-cell failure. However, in Arc*Pomc*^−/−^ mice, glucose-stimulated insulin secretion is not impaired, probably due to elevated glycosuria. These data are in agreement with a report indicating the beneficial effects of elevated glycosuria on β-cell function in SGLT2 knockout mice [@bib70].

In addition to elevated glycosuria, Arc*Pomc*^−/−^ mice manifested increased natriuresis, kaliuresis and chloriuresis. The function of RSNA in sodium reabsorption is well documented [@bib71]. Reduced RSNA leads to elevated natriuresis. Moreover, epinephrine is also involved in potassium and chloride homeostasis. Epinephrine treatment increases potassium and chloride reabsorption [@bib72]. Hence, suppressed RSNA may also explain the elevated kaliuresis and chloriuresis in Arc*Pomc*^−/−^ mice. Renal denervation in WT and diabetic *db/db* mice recapitulated the phenotype of increased natriuresis, kaliuresis, and chloriuresis observed in Arc*Pomc*^−/−^ mice ([Figure 7](#fig7){ref-type="fig"}).

In summary, we report that ArcPOMC is essential in maintaining basal RSNA in mice. We have also demonstrated the critical function of RSNA in glucose reabsorption. Reduced RSNA in Arc*Pomc*^−/−^ mice as well as renal denervation in WT and diabetic *db/db* mice improves their glucose tolerance by elevating glycosuria via reduced proximal tubular GLUT2 levels (see Graphical Abstract). Therefore, elevated glycosuria is likely a mechanism for improving glucose tolerance after renal denervation in drug resistant hypertensive patients.
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